Functional characterisation of missense ceruloplasmin variants and real-world prevalence assessment of Aceruloplasminemia using population data.

EBioMedicine

Department of Research & Innovation, Kedrion Biopharma S.p.A, Via di Fondovalle, Loc. Bolognana, Gallicano 55027, Italy. Electronic address:

Published: March 2025

Background: Aceruloplasminemia (ACP) is a rare recessive disease caused by loss of ceruloplasmin activity due to pathogenic variants in the ceruloplasmin (CP) gene. ACP causes iron accumulation in various organs, leading to neurodegeneration, anaemia, and diabetes. Estimating ACP prevalence is challenging, particularly as missense variants are not readily identified as pathogenic.

Methods: Heterozygous missense variants likely to impact function were mapped in gnomAD and representative examples analysed for effects on CP activity. This knowledge was complemented by prediction of destabilizing effects of potentially pathogenic missense variants and integrated with loss-of-function mutations. Global ACP prevalence was predicted and compared with a more traditional method.

Findings: Several as yet uncharacterised missense CP variants of pathogenic interest were identified by structure-function in-silico analysis. A representative subset was functionally validated, together with known ACP missense variants. Insights on the relative importance of copper ions coordinating centres in CP and its substrate specificity were discovered. Overall, a destabilizing effect was predicted for 130 missense CP variants. This information, integrated with known ACP missense and loss-of-function CP variants in gnomAD, allowed an estimation of ACP prevalence of 12.6/10. An alternative analysis based on minor allele frequency ≤0.01 resulted in an ACP prevalence as high as 8/10.

Interpretation: These prevalence estimates for ACP are 20-25-fold higher than previously estimated and underscore the applicability of structure-function based analyses of real-world genetic variability to provide an alternative method for representing the frequency of rare disease variants.

Funding: REACT-EU PON 2014-2021, Kedrion S.p.A.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ebiom.2025.105625DOI Listing

Publication Analysis

Top Keywords

missense variants
24
acp prevalence
16
variants
9
acp
9
missense
8
variants integrated
8
acp missense
8
prevalence
6
functional characterisation
4
characterisation missense
4

Similar Publications

Two New Kindreds with Complete Factor D Deficiency.

Eur J Immunol

March 2025

Department of Immunology, Assistance Publique- Hôpitaux de Paris (AP-HP), Georges Pompidou European Hospital, Paris, France.

Inborn deficiencies of the alternative pathway (AP) of the complement system have been associated with life-threatening infections, mainly by encapsulated bacteria. Complete factor D (FD) deficiencies have been reported in only seven families in the literature. We report two new cases of biochemically and genetically confirmed complete FD deficiency, including the first in a Down syndrome patient.

View Article and Find Full Text PDF

Objective: Heterozygous germline loss-of-function variants in AIP are associated with young-onset growth hormone and/or prolactin-secreting pituitary tumours. However, the pathogenic role of the c.911G>A; p.

View Article and Find Full Text PDF

In recent years, numerous genetic variants have been linked with prelingual hearing loss (HL). Variants in the LOXHD1 gene (lipoxygenase homology domain-1) associated with DFNB77 are highly heterogeneous, with different auditory characteristics varying from stable to progressive and mild to profound. To date, 168 DFNB77 cases have been recorded worldwide.

View Article and Find Full Text PDF

Hematological ABP: Interest of New Generation Sequencing Methods (NGS) to Study Suspicious Fluctuations in Erythropoiesis.

Drug Test Anal

March 2025

Department of Pharmacology and Toxicology, Inserm U-1018, CESP, Teams MOODS, Paris-Saclay University, Garches, France.

We present a case report of an adverse analytical finding (AAF) with suspected doping in an athlete following consumption of a supplement contaminated with Roxadustat, an oral inhibitor of hypoxia-inducible factor prolyl hydroxylase (HIP-PH), which increases erythropoietin production under normoxic conditions. Simultaneously, the athlete biological passport (ABP) profile was reviewed by experts of the World Anti-Doping Agency (WADA) ABP review panel and considered to be atypical and suspect of blood doping. A particular genetic testing was performed, which determined that this athlete had various reasons for fluctuations in her hematological parameters, such as the C677T and 1298C MTHFR mutations leading to chronic folate deficiency which can participate in the development of multiple hormonal and metabolic disturbances, heterozygous missense variant EPAS1 c.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!